Literature DB >> 31772749

MGUS bone.

Osamu Imataki1, Makiko Uemura1.   

Abstract

A 65-year-old man was referred to our hospital to undergo orthopedic surgery due to severe cervical ossification of the posterior longitudinal ligament. Computed tomography scanning showed a massive osteolytic lesion in his pelvis. Other screening examinations including detection of bone mineral density and osteoporosis biomarkers, bone scintigram and 18F-fluorodeoxyglucose-positron emission tomography were all normal. Bone marrow aspiration revealed slightly increased plasmacytes at 3.8%. These findings led to a diagnosis of monoclonal gammopathy with undetermined significance (MGUS). Architectural osteolytic bone associated with MGUS without apparent abnormality in bone mineral metabolism could be a common occurrence prior to onset or occurrence of multiple myeloma.
© The Author(s) 2019. Published by Oxford University Press.

Entities:  

Year:  2019        PMID: 31772749      PMCID: PMC6735728          DOI: 10.1093/omcr/omz082

Source DB:  PubMed          Journal:  Oxf Med Case Reports        ISSN: 2053-8855


A 65-year-old man was referred to our hospital because of severe cervical ossification of the posterior longitudinal ligament (OPLL), which needed to be operated on. He underwent screening computed tomography (CT) from the chest to the pelvis. CT findings revealed osteolytic lesions with worm-eaten appearance, especially in his pelvis (Fig. 1). We examined his bone via bone scintigram and 18F-fluorodeoxyglucose (FDG)-positron emission tomography/CT. Bone metabolism was not increased and abnormal 18F-FDG uptake was not observed. Bone marrow aspiration test results did not show plasmacytic neoplasm. Osteoresorption (TRACP-5b)/osteoplastic (bone type ALP) markers were within normal range, and serum protein fraction or electrophoresis did not indicate the presence of monoclonal protein. IgA, G or M levels did not increase. Immunoglobulin suppression was not present. Paraproteinosis was detected based on restricted serum κ/λ ratio, which was 163.0/17.10 mg/dl (9.532). The patient’s bone mineral density was within the normal range; therefore, he did not meet the diagnostic criteria for osteoporosis. Bone marrow trepan biopsy revealed normocellular marrow without neoplasm or dysplasia (Fig. 2). Plasmacytes were slightly elevated at 3.8% among all nuclear cells in the bone marrow. Our final diagnosis was monoclonal gammopathy with undetermined significance (MGUS) with associated bone lesions in the pelvis, referred to as ‘MGUS bone’. This bone is believed to develop differently from myeloma bone lesions or osteoporosis [1]. His OPLL would be treatable via orthopedic intervention, and MGUS typically does not require treatment. However, further consideration would be needed if monoclonal plasmacytes were increased. Such MGUS cases might be treated better in the future considering the background pathophysiology. The incidence and risk of any fracture increases in MGUS patients despite evidence of healthy bone mineral metabolism and density [2, 3]. This may reflect the early phase of disease-related osteopathy occurring in the natural course of plasma cell neoplasms [4]. Therefore, osteolytic lesions could be observed for monoclonal gammopathy even in the absence of bone abnormality.
Figure 1

The patient's CT findings in his pelvic bone.

Figure 2

The pathological findings of the patient's bone marrow biopsy.

The patient's CT findings in his pelvic bone. The pathological findings of the patient's bone marrow biopsy.
  4 in total

1.  Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

Authors:  Sigrun Thorsteinsdottir; Sigrun H Lund; Ebba K Lindqvist; Marianna Thordardottir; Gunnar Sigurdsson; Rene Costello; Debra Burton; Hlif Steingrimsdottir; Vilmundur Gudnason; Gudny Eiriksdottir; Kristin Siggeirsdottir; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-12-21

Review 2.  Monoclonal gammopathy of undetermined significance and bone health outcomes: a systematic review and exploratory meta-analysis.

Authors:  Nicola Veronese; Claudio Luchini; Marco Solmi; Giuseppe Sergi; Enzo Manzato; Brendon Stubbs
Journal:  J Bone Miner Metab       Date:  2017-02-27       Impact factor: 2.626

3.  Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study.

Authors:  Sigurdur Y Kristinsson; Min Tang; Ruth M Pfeiffer; Magnus Björkholm; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

Review 4.  Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?

Authors:  Song Xu; Kim De Veirman; Ann De Becker; Karin Vanderkerken; Ivan Van Riet
Journal:  Leukemia       Date:  2018-02-22       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.